Sano Tomoya, Kawaguchi Takumi, Ide Tatsuya, Amano Keisuke, Kuwahara Reiichiro, Arinaga-Hino Teruko, Torimura Takuji
Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Life (Basel). 2021 Mar 23;11(3):263. doi: 10.3390/life11030263.
Nucles(t)ide analogs (NAs) are effective for chronic hepatitis B (CHB). NAs suppress hepatic decompensation and hepatocarcinogenesis, leading to a dramatic improvement of the natural course of patients with CHB. However, renal dysfunction is becoming an important issue for the management of CHB. Renal dysfunction develops in patients with the long-term treatment of NAs including adefovir dipivoxil and tenofovir disoproxil fumarate. Recently, several studies have reported that the newly approved tenofovir alafenamide (TAF) has a safe profile for the kidney due to greater plasma stability. In this mini-review, we discuss the effectiveness of switching to TAF for NAs-related renal tubular dysfunction in patients with CHB.
核苷酸类似物（NAs）对慢性乙型肝炎（CHB）有效。NAs可抑制肝失代偿和肝癌发生，从而显著改善CHB患者的自然病程。然而，肾功能不全正成为CHB治疗中的一个重要问题。长期使用包括阿德福韦酯和替诺福韦酯在内的NAs治疗的患者会出现肾功能不全。最近，几项研究报告称，新批准的替诺福韦艾拉酚胺（TAF）由于具有更高的血浆稳定性，对肾脏具有安全性。在本综述中，我们讨论了CHB患者将治疗转换为TAF治疗NAs相关肾小管功能障碍的有效性。
